Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for researching and controlling impurity E in Valsartan

A technology of valsartan and valine ester, which is applied in the field of impurity VLSI-E research and control, and can solve the problem of inability to use gas chromatography to detect isoleucine ester, inconvenient transportation and storage, and detectors such as evaporative light Low sensitivity, failure to meet detection requirements, etc.

Active Publication Date: 2011-04-27
CHINA RESOURCES SAIKE PHARMA
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because valine ester is an oily substance, it is inconvenient during transportation and storage, and it is often prepared as a salt in industry, such as valine methyl ester hydrochloride and valine ethyl ester hydrochloride
Since the impurity control after salt formation becomes a difficult problem; the valine ester loses its volatility, and the content of the isoleucine ester in it cannot be detected by gas chromatography; there is no ultraviolet absorption, and the high performance liquid phase ultraviolet detection method, evaporative light, etc. cannot be used. The detector sensitivity is low and cannot meet the detection requirements

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for researching and controlling impurity E in Valsartan
  • Method for researching and controlling impurity E in Valsartan
  • Method for researching and controlling impurity E in Valsartan

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1. The preparation of valsartan

[0024] In a 1000ml three-necked flask, add 118g N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester and 400ml toluene, 44g sodium bicarbonate, stir, and cool to 0 ℃. Add 52ml of valeryl chloride dropwise, keeping the temperature below 10°C. After the addition was complete, it was stirred at room temperature for 10 hours; TLC and HPLC showed that the reaction was complete. Add 100ml×2 water, stir for 0.5 hours, separate the water phase; wash the toluene phase with 50ml 1N hydrochloric acid, 50ml 5% sodium bicarbonate and 50ml×2 brine, and dry with 40g anhydrous sodium sulfate. After filtration, the filtrate was rotary evaporated to obtain a light yellow oily substance, namely N-[(2'-cyanobiphenyl-4-yl)methyl]-N-pentanoyl-(L)-valine methyl ester.

[0025] Add 135ml of tributyltin chloride, 40g of sodium azide, 400ml of xylene and N-[(2'-cyanobiphenyl-4-yl)methyl]-N-pentanoyl-( L)-Valine methyl ester, heat up to 140°C ...

example 2

[0026] Example 2. Refining of Valsartan

[0027] Add the obtained valsartan crude product into 460ml of ethyl acetate, and heat until completely dissolved. After cooling to room temperature, continue to cool to 0°C for 2 hours, filter, and wash the filter cake with a small amount of cold ethyl acetate. Dry to obtain 80g valsartan primary crystallization product. Add the primary crystallization product of valsartan to 400ml ethyl acetate, heat to dissolve, stir and cool to room temperature, filter, wash the filter cake with a small amount of ethyl acetate, and dry to obtain 60g secondary crystallization product of valsartan, HPLC purity >99.7%.

example 3

[0028] Preparation of Example 3.VLSI-E

[0029] Add 12.5g of potassium carbonate and 85mL of acetonitrile into a 250ml three-necked flask, add 5.1g of L-isoleucine methyl ester hydrochloride, add 16.7g of VLS-02, and heat to 50-55°C. Reacted for 7.5h, filtered, and the filtrate was rotary evaporated under reduced pressure. The oil was dissolved in 70mL of toluene, 4.1g of sodium bicarbonate was added, and 4.6ml of valeryl chloride was added dropwise. After the addition, stir at room temperature for 3 to 4 hours. The toluene layer was washed with 30ml×2 brine, dried over anhydrous sodium sulfate, and spin-dried to obtain 21g of oil. The above oil was dissolved in 90ml of methanol, and 1ml of hydrochloric acid was added dropwise. After the addition, stir at room temperature for 3 to 4 hours. After filtration, the filtrate was spin-dried under reduced pressure to obtain 14.4 g of oil. 60ml of toluene was added to the above oil, and a solution of 5.6g of potassium hydroxide d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to a method for researching and controlling an impurity E in Valsartan. The method comprises the steps of limiting initial raw material of synthesis, using valine ester salt-forming matter of which the content of isoleucine ester salt-forming matter is not more than 0.23 percent as the initial raw material of synthesis, and obtaining the Valsartan. As the impurity VLSI-E content of the Valsartan is not more than 0.1 percent, the aim of the method can be achieved.

Description

Technical field: [0001] The invention relates to a drug detection method, in particular to a research and control method of the impurity VLSI-E in the antihypertensive drug valsartan. Background technique: [0002] Valsartan (valsartan, chemical formula see I), chemical name: N-(1-oxypentyl)-N-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-L - Valine, a type 1 form of angiotensin II (AT 1 ) receptor antagonist, with a brand-new antihypertensive mechanism, stable antihypertensive, strong curative effect, long acting time, and good patient tolerance. [0003] [0004] The literature on valsartan is quite rich, mainly focusing on the synthesis route and crystal form. For example, patents on the synthesis route of valsartan include US5399578, US7199144, WO2006067216, WO2008007391, WO2004026847, CN00115355, etc.; patents on the crystal form of valsartan There are US7105557, WO2003089417, WO2004087681, US20060270723, etc.; in terms of impurity control of valsartan, our patent CN10136...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D257/04G01N30/02
Inventor 蒋玲敏殷毅静刘蕴秀邹江杨琰王文峰
Owner CHINA RESOURCES SAIKE PHARMA